Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GERN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGERNGeron$1.48-7.2%$2.27$1.45▼$5.34$939.43M0.5415.04 million shs26.66 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGERNGeron-3.64%-9.14%-9.66%-55.08%-51.82%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGERNGeron4.369 of 5 stars4.44.00.01.31.73.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGERNGeron 2.82Moderate Buy$5.75289.83% UpsideCurrent Analyst Ratings BreakdownLatest GERN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/12/2025GERNGeronHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/12/2025GERNGeronNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.002/27/2025GERNGeronBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$9.00 ➝ $4.002/27/2025GERNGeronScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$6.00 ➝ $4.002/27/2025GERNGeronStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $4.002/27/2025GERNGeronNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.00 ➝ $5.002/27/2025GERNGeronB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$3.50 ➝ $2.002/26/2025GERNGeronHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral2/18/2025GERNGeronB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.50 ➝ $3.501/13/2025GERNGeronNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$6.00 ➝ $7.00(Data available from 4/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGERNGeron$76.99M12.20N/AN/A$0.46 per share3.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGERNGeron-$184.13M-$0.27N/AN/AN/A-682.48%-67.53%-45.46%5/1/2025 (Estimated)Latest GERN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/26/2025Q4 2024GERNGeron-$0.04-$0.04N/A-$0.04$45.29 million$47.54 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGERNGeronN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGERNGeron0.042.892.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGERNGeron73.71%Insider OwnershipCompanyInsider OwnershipGERNGeron3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGERNGeron70636.90 million585.76 millionOptionableGERN HeadlinesRecent News About These CompaniesLevi & Korsinsky Notifies Shareholders of Geron Corporation (GERN) of a Class Action Lawsuit and an Upcoming DeadlineApril 1 at 1:22 PM | globenewswire.comClass Action Filed Against Geron Corporation (GERN) - May 12, 2025 Deadline to Join - Contact Levi & KorsinskyApril 1 at 12:30 PM | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Geron Corporation and Certain Officers - GERNApril 1 at 11:55 AM | accessnewswire.comShareholders of Geron Corporation Should Contact Levi & Korsinsky Before May 12, 2025 to Discuss Your Rights - GERNApril 1 at 7:25 AM | accessnewswire.comGERN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Geron Corporation Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!April 1 at 7:00 AM | accessnewswire.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 12, 2025 in Geron Corporation Lawsuit - GERNApril 1 at 5:45 AM | prnewswire.comGERN REMINDER: Kessler Topaz Meltzer & Check, LLP Urges GERN Investors with Losses to Contact the FirmMarch 31 at 9:43 PM | theglobeandmail.comLevi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Geron Corporation (GERN) ShareholdersMarch 31 at 7:45 PM | accessnewswire.comClass Action Announcement for Geron Corporation Investors: A Securities Fraud Class Action Lawsuit Was Filed Against Geron Corporation - Contact Kessler Topaz Meltzer & Check, LLPMarch 31 at 7:28 PM | prnewswire.comContact Levi & Korsinsky by May 12, 2025 Deadline to Join Class Action Against Geron Corporation(GERN)March 31 at 5:15 PM | accessnewswire.comGeron Corp.: A Compelling Potential Buying Opportunity Thanks To Bearish CommentsMarch 31 at 5:14 PM | seekingalpha.comGeron Plans to Announce First Quarter 2025 Financial Results on May 7, 2025March 31 at 5:01 PM | businesswire.comGeron Corp.: A Compelling Potential Buying Opportunity Thanks To Bearish CommentsMarch 31 at 5:01 PM | seekingalpha.comGERN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Geron Corporation Investors with Substantial Losses Have Opportunity to Lead Investor Class Action LawsuitMarch 31 at 5:00 PM | globenewswire.comGERN Investors Have Opportunity to Lead Geron Corporation Securities Fraud LawsuitMarch 31 at 3:48 PM | prnewswire.comGeron Corporation Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 12, 2025 to Discuss Your Rights - GERNMarch 31 at 2:30 PM | accessnewswire.comGERN Stockholders Should Contact Robbins LLP for Information About How They Can Lead the Geron Corporation Class ActionMarch 31 at 2:03 PM | globenewswire.comInvestors in Geron Corporation Should Contact The Gross Law Firm Before May 12, 2025 to Discuss Your Rights – GERNMarch 31 at 1:24 PM | globenewswire.comClass Action Filed Against Geron Corporation (GERN) - May 12, 2025 Deadline to Join - Contact Levi & KorsinskyMarch 31 at 1:15 PM | accessnewswire.comROSEN, A LONGSTANDING LAW FIRM, Encourages Geron Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – GERNMarch 31 at 1:11 PM | globenewswire.comSegall Bryant & Hamill LLC Buys 3,369,196 Shares of Geron Co. (NASDAQ:GERN)March 26, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGERN Company DescriptionsGeron NASDAQ:GERN$1.48 -0.12 (-7.23%) As of 02:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy Amazon Falls Back to a Key Support Line: Here's How to Play It Berkshire Hathaway Gains Defy Stock Market Slump Tech Sell-Off Makes Microsoft Stock Look Like a Steal Palantir Stock Builds Momentum on New Partnership Amprius Market Gets Amped Up on Growth Outlook 3 Buyable Stocks With Solid Bottoms Ready to Rebound Game-Changing News for Advanced Micro Devices Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
